Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-mabHDI plus ABVD in Lymphocytic Predominant Hodgkin's Lymphoma
NCT00816959Phase 3Unknown
- Sponsor
- American Scitech International
- Start
- Jul 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab + ifosfamide in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), sponsored by American Scitech International. Status: unknown.
02
Drugs
rituximab + ifosfamide
03
Conditions
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
Beyond the preview
Go deeper on NCT00816959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00816959.